特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
649742

免疫療法薬の世界市場:成長率、動向および予測分析(2020年~2025年)

Immunotherapy Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 116 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.81円
免疫療法薬の世界市場:成長率、動向および予測分析(2020年~2025年)
出版日: 2020年08月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 116 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の免疫療法薬市場は、2019年から2024年までの予測期間中に13%のCAGRで成長すると予想されています。免疫療法薬市場の成長に寄与する主な要因には、従来の治療法よりも標的療法の採用が増えていること、バイオシミラーの出現、慢性疾患や生活習慣病の有病率の上昇、モノクローナル抗体の需要の高まりなどがあります。

当レポートでは、世界の免疫療法薬市場について調査分析し、市場概要、市場力学、市場区分、地域別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査の成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 従来の療法よりも標的療法の採用が増えている
    • バイオシミラーの出現
    • 慢性疾患と生活習慣病の有病率の上昇
    • モノクローナル抗体の需要の高まり
  • 市場の阻害要因
    • 免疫療法治療の高コスト
    • 製品開発サイクルでの高い損耗率
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 競争力の強さ

第5章 市場のセグメンテーション

  • 薬物の種類別
    • モノクローナル抗体
    • ワクチン
    • 免疫チェックポイント阻害剤
    • インターフェロンアルファおよびベータ
    • インターロイキン
    • その他
  • 治療分野別
    • 自己免疫疾患および炎症性疾患
    • 感染症
    • その他
  • エンドユーザー別
    • 病院/診療所
    • 癌研究センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業概要
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • UbiVac

第7章 市場機会および将来動向

目次
Product Code: 60463

The immunotherapy drugs market is anticipated to record a CAGR of 13% during the forecast period. The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders, and rising demand for monoclonal antibodies. Furthermore, immunotherapy is widely used in cancer treatment

For instance, over the past decade, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune-based therapies. Some of the major chronic diseases include cancer, kidney failure, and heart diseases. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization. Thus, the rise in the number of diseases and associated disorders is among the major primary reasons for the growth of this immunotherapy drugs market.

Key Market Trends

Cancer is Expected to Hold the Major Share in the Therapy Area Segment

  • Cancer is an abnormal growth of the cells in the body. There are more than 100 different types of cancer. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. This cancer prevalence is expected to be the same in the coming years, which is helping the market to grow.
  • There are several types of immunotherapies used for the treatment of cancer. Some of the immunotherapies include immune checkpoint inhibitors, T-cells cell transfer, cancer vaccines, and immune system modulators.​
  • These therapies are used for many types of cancer and their advanced stages. The side-effects of cancer immunotherapy vary, depending upon the immunotherapy being used. Some of the popular immunotherapy drugs are Rituxan, Yervoy, Adcetris, and Zevalin, among several others.​
  • The growth of immunotherapies in developed markets is high, due to increased R&D, with better government policies for supporting clinical trials through findings and campaigns, in order to raise awareness regarding several kinds of cancer.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to have a significant market share throughout the forecast period. This is due to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region.

According to the estimates of the American Cancer Society, in 2018, there would be 1,735,350 new cancer cases diagnosed and 609,640 deaths, due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.​

In the North American region, the United States holds the largest market share. Factors, such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure, and rising prevalence of chronic and lifestyle disorders are the primary factors propelling the immunotherapy market in the United States. In March 2019, Roche's Tecentriq in combination with Abraxane received U.S.FDA accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer. Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer.

Competitive Landscape

The immunotherapy drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches R&D, expansions to gain competitive advantage. In August 2019, U.S.FDA approved pexidartinib (TURALIO, Daiichi Sankyo) capsules for adult patients with symptomatic tenosynovial giant cell tumor (TGCT). Some of the major players of the market are AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Adoption of Targeted Therapy over Traditional Therapy
    • 4.2.2 Emergence of Biosimilars
    • 4.2.3 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
    • 4.2.4 Rising Demand for Monoclonal Antibodies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Immunotherapy Treatment
    • 4.3.2 High Attrition Rate in the Product Development Cycle
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Drug
    • 5.1.1 Monoclonal Antibodies
    • 5.1.2 Vaccines
    • 5.1.3 Interferons Alpha and Beta
    • 5.1.4 Interleukins
    • 5.1.5 Other Types of Drugs
  • 5.2 By Therapy Area
    • 5.2.1 Cancer
    • 5.2.2 Autoimmune and Inflammatory Diseases
    • 5.2.3 Infectious Diseases
    • 5.2.4 Other Therapy Areas
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 AstraZeneca plc
    • 6.1.4 Bristol-Myers Squibb
    • 6.1.5 F. Hoffmann-La Roche AG
    • 6.1.6 GlaxoSmithKline plc
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 UbiVac

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.